Page 1 of 1

Moderna Starts Human Trials Of mRNA Vaccine For Virus That Likely Causes MS

Posted: Fri Jan 14, 2022 11:41 am
by Tif
"TOPLINE Moderna recently launched early stage clinical trials for an mRNA vaccine against the Epstein-Barr virus (EBV), a common pathogen that infects almost everyone at some point in their lives, is the primary cause of mononucleosis and, according to a study published in the journal Science Thursday, likely causes multiple sclerosis (MS), offering hope the devastating neurological condition might be prevented. ........"

https://www.forbes.com/sites/roberthart ... 8304e01a04

mRNA-1189 Epstein-Barr Virus Vaccine Description/Clinical Trials

Posted: Sat Jan 15, 2022 3:17 pm
by Tif
mRNA-1189

https://www.precisionvaccinations.com/v ... us-vaccine

...................."mRNA-1189 Epstein-Barr Virus Vaccine Clinical Trials
Moderna has begun dosing their first participant in the Phase 1 clinical trial. Clinical Trial NCT05164094: A Study of an Epstein-Barr Virus Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults. Participants will receive three intramuscular (IM) injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.

Contact: Moderna Clinical Trials Support Center1-877-777-7187clinicaltrials@modernatx.com. "

Re: Moderna Starts Human Trials Of mRNA Vaccine For Virus That Likely Causes MS

Posted: Sat Jan 15, 2022 9:35 pm
by NHE
Clinicaltrials.gov info...

https://clinicaltrials.gov/ct2/show/NCT05164094

Estimated completion date: June 24, 2023

Re: Moderna Starts Human Trials Of mRNA Vaccine For Virus That Likely Causes MS

Posted: Tue Jan 18, 2022 2:29 pm
by frodo
Thanks!!!

Re: Moderna Starts Human Trials Of mRNA Vaccine For Virus That Likely Causes MS

Posted: Sat Sep 23, 2023 2:02 am
by NHE
NHE wrote: Sat Jan 15, 2022 9:35 pm Clinicaltrials.gov info...

https://clinicaltrials.gov/ct2/show/NCT05164094

Estimated completion date: June 24, 2023
The estimated completion date of this study has been extended to June 2025. The study is still recruiting healthy volunteers.